Literature DB >> 2440565

Potentiation of radiation cytotoxicity by recombinant interferons, a phenomenon associated with increased blockage at the G2-M phase of the cell cycle.

A Y Chang, P C Keng.   

Abstract

Radiation sensitivity of human hypernephroma tumor cells, ACHN, was evaluated in the presence or absence of various recombinant interferons (IFNs): alpha D (rHuIFN-alpha D), beta ser (rHuIFN-beta ser), and gamma (rHuIFN-gamma). Exponentially growing monolayers of ACHN cells were incubated with IFNs (10(3) units/ml) for 2, 6, and 24 h prior to irradiation. The effects of IFNs on the growth inhibition, radiation cell survival, and cell cycle redistribution were determined from growth curves, colony-forming efficiency, and flow cytometric analysis. rHuIFN-alpha D and rHuIFN-beta ser were associated with a modest inhibition in cell growth and the growth delay was reversible upon the removal of IFNs. However, rHuIFN-gamma exhibited the greatest inhibitory effect on both cell growth delay and rate. IFN and radiation have an additive effect on cell growth inhibition. Although IFN treatments alone (0-1000 IU/ml) did not have a significant effect on cell survival, radiation killing was increased by IFN pretreatment. The enhancing factor measured at a survival level of 0.1 for rHuIFN-alpha D, rHuIFN-beta ser, and rHuIFN-gamma was 1.21, 1.28, and 1.44, respectively. In addition, this potentiation effect was dependent on the dose of radiation and exposure time to IFN with the maximal effect observed after 24 h of treatment with IFN at 12 Gy. When the distributions of G1, S, and G2-M cells were measured 24 and 48 h after combined IFN and radiation treatment, there was a significant increase in the accumulation of cells at the G2-M phase of the cell cycle compared to either IFN or radiation treatment alone. We conclude that IFNs and radiation have an additional inhibitory effect on ACHN cell growth, that IFN can potentiate radiation cytotoxicity, and that this phenomenon is associated with an increased blockage at G2-M phase of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440565

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer-siRNA Chimeras in Human Tumor Xenografts.

Authors:  Xiaohua Ni; Yonggang Zhang; Kenji Zennami; Mark Castanares; Amarnath Mukherjee; Raju R Raval; Haoming Zhou; Theodore L DeWeese; Shawn E Lupold
Journal:  Mol Cancer Ther       Date:  2015-10-05       Impact factor: 6.261

2.  Unexpected radiation protection with 13-cis-retinoic acid plus interferon alpha-2a.

Authors:  K A Mason; P J Tofilon
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  [Treatment of stage IIIB loco-regionally advanced non-small-cell bronchial carcinomas with radiation and interferon-beta. Preliminary results of a phase II study].

Authors:  J Bund; K Eberhardt; W Hartmann; H J Habermalz
Journal:  Strahlenther Onkol       Date:  1998-06       Impact factor: 3.621

4.  Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study.

Authors:  E E Vokes; D J Haraf; P C Hoffman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 5.  Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.

Authors:  Christopher A Barker; Michael A Postow
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-01       Impact factor: 7.038

Review 6.  The influence of radiation in the context of developing combination immunotherapies in cancer.

Authors:  Jamie Honeychurch; Timothy M Illidge
Journal:  Ther Adv Vaccines Immunother       Date:  2018-01-24

7.  Alteration of tumour response to radiation by interleukin-2 gene transfer.

Authors:  J Lee; J P Moran; B M Fenton; C J Koch; J G Frelinger; P C Keng; E M Lord
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

8.  An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.

Authors:  Laura Lasagni; Michela Francalanci; Francesco Annunziato; Elena Lazzeri; Stefano Giannini; Lorenzo Cosmi; Costanza Sagrinati; Benedetta Mazzinghi; Claudio Orlando; Enrico Maggi; Fabio Marra; Sergio Romagnani; Mario Serio; Paola Romagnani
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.